Decreased Mortality in a Large Cohort of COVID-19 Patients


Coronavirus disease 2019 (COVID-19) convalescent plasma has emerged as a promising therapy and has been granted Emergency Use Authorization by the US Food and Drug Administration for hospitalized COVID-19 patients. The American Journal of Pathology(AJP) recently reported results from an interim analysis of a propensity score-matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high-titer anti-spike protein receptor-binding domain (RBD) IgG significantly decreases mortality. Check out the full story published by the American Journal of Pathology(AJP) right here.

0 comments

© 2021 by Covid Plasma Initiative Foundation

The Yitzchok Lebovits COVID Plasma Initiative is dedicated in memory of R’ Yitzchok a"h Ben R’ Moshe Eliezer y"blt, who recently passed away. R' Yitzchok was a brother of Chaim Lebovits who has been a driving force behind every aspect of this initiative to bring this life-saving therapy to the people who need it.